Stigma and Efficacy of Zhizhu Kuanzhong Capsules Versus Doxepin in the Treatment of Refractory Functional Dyspepsia: A Randomized Controlled Trial.
Stigma and Efficacy of Zhizhu Kuanzhong Capsules Versus Doxepin in the Treatment of Refractory Functional Dyspepsia: A Randomized Controlled Trial.
复制标题
在难治性功能性消化不良治疗中，吉祖·库氏胶囊与多xepin的污名和疗效：一项随机对照试验。
DOI：
10.5056/jnm22145
复制
发表时间：
2023-07-30
影响因子：
3.4
通讯作者：
Chen SL
中科院分区：
文献类型：
--
作者：
Wang QQ;Cheng L;Wu BY;Qiu HY;Xu P;Wang B;Yan XJ;Chen SL
功能性消化不良患者普遍存在与抗抑郁药相关的污名。影响用药依从性和疗效。草药在缓解亚洲人的消化不良症状方面获得了根深蒂固的文化认同。比较枳术宽中胶囊（ZZKZ）与盐酸多塞平（Doxepin）对难治性FD（rFD）患者污名化和药物不依从性的改善作用。将2021年2月至2022年2月的rFD患者随机分配至多塞平（n = 56）或ZZKZ（n = 57）联合奥美拉唑治疗4周。分析药物拥有率（MPR）、疾病和药物相关污名。量表用于评估消化不良症状（利兹消化不良问卷）和心理状况（广泛性焦虑症问卷和患者健康问卷）。ZZKZ组MPR值明显高于多塞平组（P < 0.001）。治疗后与基线相比，治疗组患者的羞耻感评分下降，多塞平组患者的羞耻感评分上升。与多虑平相关的污名比例显著低于与ZZKZ相关的污名比例（P < 0.001）。两组MPR值与治疗后污名评分呈负相关（P < 0.001）。两组患者治疗后消化不良症状及心理状况均有改善，治疗后利兹消化不良问卷、广泛性焦虑问卷、患者健康问卷评分两组间差异无统计学意义。结论ZZKZ在减轻rFD患者的羞辱感和服药不依从性方面上级多塞平，在改善消化不良症状和心理状况方面疗效相当。
Stigma related with antidepressants is prevalent in patients with functional dyspepsia. It affects medication compliance and efficacy. Herbal medicine acquired a deep-rooted cultural identity in relieving dyspeptic symptoms in Asians. The research was designed to compare the effectiveness of Zhizhu Kuanzhong capsules (ZZKZ) versus doxepin hydrochloride (doxepin) on alleviating stigma and medication nonadherence among patients with refractory FD (rFD). Patients with rFD from February 2021 to February 2022 were randomly allocated to receive either doxepin (n = 56) or ZZKZ (n = 57) combined with omeprazole for 4 weeks. Medication possession ratio (MPR), the disease- and medication-associated stigma were analyzed. The scales were utilized to assess dyspeptic symptoms (Leeds Dyspepsia Questionnaire) and psychological conditions (Generalized Anxiety Disorder Questionnaire and Patient Health Questionnaire). The MPR values for ZZKZ were significantly higher than those for doxepin (P < 0.001). The stigma scores decreased in ZZKZ group while increased in doxepin group compared to baseline after treatment. The proportion of patients showing ZZKZ-associated stigma was significantly lower than doxepin-associated stigma (P < 0.001). The MPR values were negatively correlated with post-treatment stigma scores in both groups (P < 0.001). Dyspeptic symptoms and psychological condition were improved in both groups after treatment, with no significant difference on post-treatment Leeds Dyspepsia Questionnaire, Generalized Anxiety Disorder Questionnaire, or Patient Health Questionnaire scores between 2 groups. Conclusion ZZKZ is superior to doxepin in alleviating stigma and medication non-adherence, with comparable efficacy in improving dyspeptic symptoms and psychological condition of patients with rFD.
登录
查看更多内容
DOI：
10.1155/2022/3306420
发表时间：
2022
期刊：
Evidence-based complementary and alternative medicine : eCAM
影响因子：
--
作者：
Lee B;Ahn EK;Yang C
通讯作者：
Yang C
影响因子：
1.6
作者：
Luo，Liang;Du，Lijun;Dai，Ning
通讯作者：
Dai，Ning
影响因子：
4.3
作者：
Jiang, Shu-Man;Jia, Lin;Li, Wei-Dong
通讯作者：
Li, Wei-Dong
影响因子：
3.5
作者：
Leow, Hwong-Ruey;Ching, Siew-Mooi;Mahadeva, Sanjiv
通讯作者：
Mahadeva, Sanjiv
影响因子：
3.8
作者：
Jones, Michael P.;Keefer, Laurie;Palsson, Olafur
通讯作者：
Palsson, Olafur